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Anti-inflammatory nutrition with 
high protein attenuates cardiac 
and skeletal muscle alterations in 
a pulmonary arterial hypertension 
model
Paulien Vinke  1,2, T. Scott Bowen3, Mark. V. Boekschoten4, Renger F. Witkamp  1, 
Volker Adams5 & Klaske van Norren1
Pulmonary arterial hypertension (PAH) is characterized by remodelling of the pulmonary arteries 
and right ventricle (RV), which leads to functional decline of cardiac and skeletal muscle. This study 
investigated the effects of a multi-targeted nutritional intervention with extra protein, leucine, fish oil 
and oligosaccharides on cardiac and skeletal muscle in PAH. PAH was induced in female C57BL/6 mice by 
weekly injections of monocrotaline (MCT) for 8 weeks. Control diet (sham and MCT group) and isocaloric 
nutritional intervention (MCT + NI) were administered. Compared to sham, MCT mice increased heart 
weight by 7%, RV thickness by 13% and fibrosis by 60% (all p < 0.05) and these were attenuated in 
MCT + NI mice. Microarray and qRT-PCR analysis of RV confirmed effects on fibrotic pathways. Skeletal 
muscle fiber atrophy was induced (P < 0.05) by 22% in MCT compared to sham mice, but prevented 
in MCT + NI group. Our findings show that a multi-targeted nutritional intervention attenuated 
detrimental alterations to both cardiac and skeletal muscle in a mouse model of PAH, which provides 
directions for future therapeutic strategies targeting functional decline of both tissues.
Pulmonary hypertension (PH) is a syndrome that can result from different pathological changes in the pulmonary 
vasculature. PH is a progressive disease that is incurable and eventually lethal. An idiopathic or heritable form of 
PH, called pulmonary arterial hypertension (PAH), is the most severe form that is most commonly suffered by 
females. The prevalence of PAH in Europe is estimated as 15–100 per million persons, with 1- and 3-year survival 
rates of 87% and 67%, respectively1,2. The pathophysiology underlying PAH involves endothelial dysfunction of 
the pulmonary vasculature, metabolic abnormalities in vascular cells, hypertrophy and proliferation of smooth 
muscle cells, and uncontrolled growth of neointimal, medial, and adventitial layers that leads to thickening and 
occlusion of the small- and medium-sized pulmonary arteries3. Right ventricular (RV) remodeling is a major 
characteristic of PAH and considered to be a key mechanism driving disease progression, in which RV dysfunc-
tion is closely associated with the main symptom of exercise intolerance1. Other pathophysiological processes that 
contribute to exercise intolerance in PAH also include skeletal muscle impairments and poor nutritional status4.
Inflammation in particular is one key mechanism contributing to the pathological RV remodelling in PAH, 
which directly contributes to the development of fibrosis5,6. It has been consistently shown that the presence 
of chronic low-grade inflammation (CLGI) (e.g., elevated circulating levels of TNFα and IL-6) is linked to the 
development of cardiovascular disease7 and to changes in body composition that reduce exercise tolerance7–9. The 
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use of fish oil-derived omega-3 poly-unsaturated fatty acids (PUFAs), in particular eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) seems a promising option for the treatment of GLGI, because of their mild 
anti-inflammatory properties10. Nutritional intervention with high protein, leucine, fish oil and oligosaccharides 
has also been shown to have beneficial effects on skeletal muscle atrophy in a mouse model of cancer11. This pro-
vides evidence of a potential multi-organ treatment for PAH, where both cardiac and skeletal muscle impairments 
can be targeted in combination. Interestingly, the three known pathways involved in the development of PAH 
currently targeted by drugs1 include the endothelin, nitric oxide and prostacyclin pathways12. However while 
these drugs reduce pulmonary vascular resistance and improve survival, they do not always improve symptoms 
or address extra-cardiac maladaptations4. Thus while patients are living longer, their quality of life is still severely 
impaired due to symptoms of fatigue and exercise intolerance. A wealth of evidence in other disorders show 
that nutritional interventions can correct nutritional deficiencies, improve muscle function and exercise toler-
ance11,13,14. Nutritional strategies that target both cardiac and skeletal muscle remodelling in PAH (i.e., to provide 
a more whole-body approach) remain poorly developed, but can be of great clinical importance.
Given the adverse effects associated with PAH on multiple-organs, and the underlying role of chronic inflam-
mation in this process, the present study aimed to test whether an anti-inflammatory nutritional intervention 
high in protein, fish oil and oligosaccharides could attenuate both cardiac and skeletal muscle remodelling in 
PAH. We induced PAH by injection of monocrotaline (MCT) for 8 weeks (a validated animal model for PAH15,16) 
in female mice to account for the current sex-dependent incidence rate of PAH in humans.
Results
Weight development. Consistent with previous data16, MCT injections over an 8 week period resulted in 
a significantly reduced body weight increase over time when compared to sham animals. The increase in body 
weight was 7.4 ± 1.5% for sham mice, whereas MCT mice only increased weight by 2.3 ± 3.2% and MCT mice 
receiving nutritional intervention (MCT + NI) increased weight by 2.1 ± 4.9%: (Fig. 1A). The change in body 
weight was not due to a lower food intake in the MCT group compared to the sham group, as cumulative food 
intake of the mice was identical at the end of the intervention (see Supplementary Fig. S1).
Development of pulmonary congestion and cardiac remodeling. Compared to sham mice, MCT mice 
showed an increase in pulmonary congestion (Fig. 1B), heart weight corrected for tibia length (6.30 ± 0.62 mg/mm 
Figure 1. Total body weight development, lung weight and cardiac hypertrophy after 8 weeks of MCT injection. 
(A) Compared to sham mice, relative body weight was impaired (p < 0.05) in MCT and MCT + NI by 5%. (B) 
Both MCT groups showed an increase in lung weight (p < 0.05) compared to shams. (C) An increase in heart 
weight of MCT mice compared to shams was also seen, however these alterations were attenuated in MCT + NI 
mice. (D) Right ventricle thickness was increased only in MCT mice. (*p < 0.05, **p < 0.01) Scatterplots of the 
depicted data can be found in Supplementary Fig. S4.
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vs 5.95 ± 0.29 mg/mm) (Fig. 1C) and right ventricular thickness (0.53 ± 0.03 mm vs 0.48 ± 0.05 mm) (Fig. 1D) (all 
p < 0.05). These are signs of the development of pulmonary hypertension and subsequent RV hypertrophy in the 
MCT group. In the MCT + NI group, heart weight was not different from sham mice and reduced compared to 
MCT mice (p < 0.01) (Fig. 1C). Pulmonary congestion was increased in the MCT + NI group compared to sham 
mice (p < 0.05) and not different from the MCT group (Fig. 1B). RV thickness in the MCT + NI group was atten-
uated compared to the MCT group, such that no difference was detected compared to sham mice (Fig. 1D). There 
were no significant changes in the thickness of the left ventricle and the septum.
Anti-fibrotic effect of the nutritional intervention on the right ventricle. Histological analysis 
showed a 1.6 fold change increase in fibrosis of the RV in the MCT group compared to sham (p < 0.05), that 
was normalized in the group receiving nutritional intervention (p < 0.05) (fold change of 1.02 versus sham) 
(Fig. 2A,B). Comparison of genes from the microarray analysis showed 245 genes that were differentially regu-
lated (p < 0.05) when comparing MCT vs Sham and MCT + NI vs MCT group (Figs 3A and S2), with several of 
these genes involved in fibrosis. Using a cut-off of p < 0.01, 32 significantly differentially expressed genes were 
detected (Fig. 3B). Two of these genes are involved in fibrotic pathways (TGFb1I1 and ADAMTS-1).
Gene Set Enrichment Analysis (GSEA) of the RV of a representative subset of three mice showed overrep-
resentation of fibrotic pathways upon MCT injection (MCT vs. Sham) (no FDR q-value cut-off was used; the 
complete datasets were added as supplementary data). Upon nutritional intervention, fibrotic pathways were 
underrepresented in MCT + NI versus MCT (supplementary data). GSEA of the RV also showed underrep-
resentation of pathways involved in energy metabolism and mitochondrial function in MCT versus Sham. Upon 
nutritional intervention, these pathways were overrepresented (Supplementary Data).
Validation of the microarray data on right ventricular fibrosis. Next, we validated the two fibrotic 
genes (TGFb1I1 and ADAMTS-1) with a significance level of p < 0.01 in the microarray analysis in all our sam-
ples by qRT-PCR. We also validated two genes with a significance level of p < 0.05 (VCAN and Col14a1) by 
qRT-PCR. This confirmed upregulation of fibrotic genes in the right ventricle in MCT vs Sham and downregula-
tion in MCT + NI vs MCT (Fig. 4). MCT injection induced a 2-fold increase in VCAN mRNA expression relative 
to sham mice (p < 0.001, Fig. 4A). In MCT-injected mice receiving nutritional intervention, this increase was 80% 
lower (p < 0.01, Fig. 4A). For ADAMTS-1, the effect was similar, with a 2.5-fold increase in MCT versus sham 
mice (p < 0.001) and only 1.25-fold increase in MCT-injected mice receiving nutritional intervention (p < 0.05, 
Fig. 4B). Col14a1 mRNA expression was increased 1.35-fold in MCT-injected mice relative to sham (p < 0.05), 
although the expression normalized in MCT mice receiving nutritional intervention (p < 0.05, Fig. 4C). mRNA 
expression of TGFb1I1 was increased by 65% in MCT-injected mice compared to sham (p < 0.05). The increase 
in MCT-injected mice receiving nutritional intervention showed no significant effect (p = 0.18, Fig. 4D).
Figure 2. Nutritional intervention prevents increased right ventricular fibrosis after MCT injection. Right 
ventricular fibrosis was increased in MCT mice (p < 0.05) compared to shams and attenuated in MCT + NI 
mice. (*p < 0.05) A scatterplot of the depicted data can be found in Supplementary Fig. S4.
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Effect of nutritional intervention on inflammation markers in the right ventricle. Next to higher 
mRNA levels of fibrotic genes, we could also show that MCT injection induced a 5.5-fold increased level of 
tumor necrosis factor alpha (TNFα) in the right ventricle of MCT mice relative to sham mice (p < 0.05, Fig. 5A). 
In MCT-injected mice receiving the nutritional intervention, this increase was only 2.26 fold (Fig. 5A). COX-2 
mRNA levels also tended to be increased in right ventricle of MCT compared to sham and MCT + NI mice, 
although the effect was not significant (p = 0.068, Fig. 5B). These results suggest an anti-inflammatory effect of 
the nutritional supplement.
Effect of nutritional intervention on the skeletal muscle. The weight of the tibialis anterior (TA) 
muscle was similar in all groups (Fig. 6A), however fiber cross-sectional area (CSA) of the TA muscle was reduced 
(P < 0.05) by 22% in MCT compared to sham mice, but preserved in the MCT + NI group (1503 vs. 1178 vs 1495 
µm2, respectively) (Fig. 6B). Protein expression of the key E3 ligase MuRF1 was reduced by 30% in the group 
receiving nutritional intervention compared to MCT mice alone (p < 0.05) (Fig. 7A). The E3 ligase MuRF2 was 
increased by 41% (p < 0.05) in the MCT group compared to sham. Nutritional intervention reduced MuRF2 
protein levels by 28% (p < 0.05) (Fig. 7B). The weight of the extensor digitorum longus (EDL) muscle was similar 
in all groups (Fig. 6C). However, fiber cross-sectional area was reduced by 29% (p < 0.05) in the MCT mice com-
pared to sham, and preserved in the MCT + NI group (764 vs 542 vs 742 µm2, respectively) (Fig. 6D). The weight 
of the soleus muscle was also similar in all groups (Fig. 6E), with no effect of MCT or nutritional treatment on 
muscle fiber cross-sectional area (Fig. 6F).
Discussion
The objective of this study was to assess the impact of a targeted nutritional intervention on both cardiac and 
skeletal muscle remodeling in a PAH model induced by MCT in mice. Indeed, adding more protein, leucine, 
fish oil and oligosaccharides to the feed caused an attenuation of RV hypertrophy, fibrosis and inflammation, 
while simultaneously preventing skeletal muscle atrophy. To our knowledge, this is the first study to show that 
PAH-associated pathological changes in both cardiac and skeletal muscle can be attenuated simultaneously by 
multiple-target nutritional intervention.
This is of great clinical importance, since current treatment options do not target both the cardiac and skel-
etal muscle alterations in PAH. If nutritional intervention can prevent such pathological changes and reduce 
the development of exercise intolerance leading to an impaired quality of life, this is an important step forward. 
Figure 3. Differential expression of genes in the right ventricle after MCT injection. (A) A total of 245 genes 
were differentially expressed in MCT compared to Sham and MCT + NI compared to MCT, using a cutoff of 
p < 0.05. (B) (A) Heatmap showing 32 genes that are differentially expressed in MCT compared to sham and in 
MCT + NI compared to MCT, using a cutoff of p < 0.01.
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Further studied are needed to check whether targeted nutritional intervention can improve physical status and 
wellbeing in PAH patients.
Eight weekly injections with MCT induced a clear PAH phenotype in mice with RV hypertrophy. Histological 
analysis of the RV showed an increase in fibrotic tissue in the mice receiving MCT-injections which clearly indi-
cates cardiac remodelling typical of PAH3,17. The MCT mice receiving nutritional intervention did not show 
increased RV hypertrophy nor fibrosis. Microarray analysis of the RV and subsequent verification of the results 
Figure 4. Fibrotic genes were upregulated in MCT, but not in MCT + NI goup. Compared to sham mice, 
mRNA levels of genes involved in fibrosis were upregulated in MCT mice, but not in MCT + NI mice 
(*p < 0.05, **p < 0.01, ***p < 0.001). (VCAN: versican; ADAMTS-1: a disintegrin and metalloproteinase with 
thrombospondin motifs 1; Col14a1: collagen type XIV alpha 1; TGFb1I1: transforming growth factor beta 1 
induced transcript 1).
Figure 5. Nutritional intervention reduces an increase in TNFα mRNA levels in the right ventricle. (A) MCT 
injection induced a 5.5-fold increased level of TNFα mRNA in the right ventricle of MCT relative to sham 
mice. In MCT + NI mice this increase was only 2.26 fold. (B) COX-2 mRNA levels tended to be increased 
in right ventricle of MCT compared to sham mice (p = 0.068). TNFα: tumor necrosis factor alpha; COX2: 
cyclooxygenase-2. (*p < 0.05).
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by qRT-PCR showed that nutritional intervention prevented an increase of mRNA levels of fibrotic genes after 
MCT-injection in nearly all four genes. Probably the study was not powered to detect significant changes in all 
the genes studied. Microarray GSEA also showed downregulation of pathways involved in energy metabolism 
and mitochondrial function in mice receiving MCT-injections. Metabolic remodeling is another symptom of 
PAH. A switch from fatty acid metabolism and oxidative phosphorylation to the energetically inefficient aerobic 
glycolysis (also called the Warburg effect), is often seen17–19. Our GSEA clearly showed the downregulation of 
genes in energy metabolism and mitochondrial function in MCT compared to sham mice, suggesting a metabolic 
switch from FA oxidation to glycolysis. It also showed that this effect was reduced in the MCT group receiving the 
nutritional intervention.
A possible explanation for these findings is a reduction in inflammation due to the effect of added omega 
3 fatty acids EPA and DHA. The mRNA levels of TNFα in the RV of the MCT mice were higher compared to 
sham mice. This effect was reduced upon nutritional intervention. This theory is supported by other studies 
using the monocrotaline model in male rats, showing reduction of PAH symptoms when anti-inflammatory 
treatments were provided. Anti-inflammatory drugs such as acetylsalicylic acid (aspirin)20,21 or 5-aminosalicylic 
acid22 have produced improvements in right ventricular systolic pressure (RVSP), RV hypertrophy and pul-
monary artery remodeling. Next to this, there are also indications that certain nutritional supplements with 
anti-inflammatory properties including resveratrol23–25 and betaine26 reduce the effects of PAH in the MCT rat 
model. Supplementation with branched chain amino-acids has been described to preserve cardiac function and 
prolonged survival in a cancer cachexia mouse model27. Moreover, a diet high in leucine provided after a myocar-
dial infarction in mice was reported to decrease fibrosis and apoptosis, and improve cardiac structure28.
Injection with MCT induced a reduction of muscle fiber CSA in the TA and EDL, but did not lead to alter-
ations in the soleus. This might be due to the fact that the soleus has a more oxidative phenotype, reflected by a 
higher content of mitochondria, which might provide a certain level of protection against muscle wasting29. In 
addition, the soleus is more resistant to fatigue due to a relatively lower presence of glycolytic type II (fast twitch) 
muscle fibers, which are predominant in the EDL and TA30. The nutritional intervention was able to prevent the 
reduction in muscle fiber CSA in TA and EDL, indicating an anti-atrophic effect. This was confirmed by a reduced 
upregulation of the E3 ligases MuRF1 and MuRF2, which promotes muscle wasting by increasing protein degra-
dation via ubiquitination31.
Faber et al. reported that the same nutritional combination as used in our study reduced plasma TNFα and 
prostaglandin E2 (PGE2) in a mouse cancer cachexia model32. Both PGE2 and TNFα have been reported to induce 
MURF1 induction, leading to elevated proteolysis and increased protein breakdown8,33. When TNFα is decreased 
due to attenuated inflammatory tone, protein breakdown in the skeletal muscle is decreased, explaining the effects in 
the TA. Furthermore, skeletal muscle protein synthesis is stimulated by branched chain amino acids, especially leu-
cine34, which was added to the nutritional intervention. The effect on the skeletal muscle can be direct, by a reduction 
of inflammation and therefore protein breakdown in the muscle itself, or indirect by a reduction in disease severity.
Figure 6. Changes in skeletal muscle weight and muscle fiber cross-sectional area. (A) Weight of the tibialis 
anterior (TA) muscle was unchanged, (B) but muscle fiber cross-sectional area (CSA) of the TA was reduced 
by 22% in MCT mice compared to sham, but unaltered in MCT + NI. (B) Weight of the EDL muscle was 
unchanged, but (D) skeletal muscle fiber CSA of the EDL was reduced by 29% in the MCT mice compared 
to sham and preserved in the MCT + NI group(*p < 0.05). (E) Weight of the soleus muscle was similar in all 
groups and (F) skeletal muscle fiber CSA was also unchanged.
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Chronic low-grade inflammation (CLGI) is an important part of the pathophysiology of PAH35. Potential trig-
gers for CLGI in PAH include chronic hypoxia, mechanical stretch, mitochondrial dysfunction and systemic com-
plications such as changes in intestinal functioning (barrier function, dysbiosis etc.)9,36,37. Chronic inflammation 
and expression of pro-inflammatory cytokines such as interleukin 6 (IL-6) and TNFα are known to contribute 
to muscle wasting which is also seen in PAH13,38,39. Fish oil containing (EPA) and (DHA) can influence inflam-
matory processes by changing the production of pro- or anti-inflammatory cytokines40. Other nutritional com-
ponents, such as galacto- and fructo-oligosaccharides, can restore the microbial balance in case of dysbiosis7,41  
and also have anti-inflammatory and immune-regulating effects42. Galacto- and fructo-oligosacharides have been 
shown to be able to restore T cell function during chronic inflammation in a murine tumor model when com-
bined with omega-3 fatty acids and high quality and quantity protein32. Increased intake of high quality protein 
and the anabolic amino acid leucine can also help prevent muscle wasting11,34, which is why the combination of 
extra protein, leucine, fish oil and oligosaccharides was chosen for this study. It is unclear whether it is the whole 
combination or just a subset of the nutrients from the nutritional intervention that is responsible for the effects 
observed in this study. Further studies are warranted to reveal this aspect.
The model used for this study is an adapted version of our recently developed cachectic mouse model with 
monocrotaline-induced RV heart failure16. The adaptation concerns the control diet and the length of time the 
animals are in the experiment. The result is a model with similar RV remodeling but a more modest loss of body 
weight, which more closely resembles the clinical situation in PAH. The presence of both pulmonary congestion 
and RV hypertrophy, shows that this method produces effects comparable to those seen in the male rat model43 
that is widely accepted as a model for PAH. RV thickness increased, but we found no change on the septum and 
thickness of the left ventricle, showing that the monocrotaline mostly affects the RV. An additional advantage 
of the present model is that it concerns female animals, which is more in line with the notion that PAH occurs 
mostly in women1,3.
Figure 7. An increase in E3 ubiquitin-protein ligases MuRF1 and MuRF2 in MCT mice is prevented by 
nutritional intervention. (A) Protein levels of the key E3 ligase MuRF1 was reduced by 30% in the group 
receiving nutritional intervention compared to MCT mice alone. (B) The E3 ligase MuRF2 was increased 
by 41% in the MCT group compared to sham. Nutritional intervention reduced MuRF2 protein levels by 
28%. (*p < 0.05). Pictures are cropped from full-length pictures of blots. Full-length blots are presented in 
Supplementary Fig. S3. A MuRF1 knock-out (KO) sample was included to separate the MuRF1 bands from 
other bands due to nonspecific binding of the antibody.
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Conclusion
A multi-compound nutritional intervention providing higher amounts of protein, leucine, fish oil and oligosac-
charides significantly attenuated cardiac and skeletal muscle changes in a female mouse model of pulmonary 
hypertension. The effect on the development of fibrosis in the RV was the most profound and is at least partly due 
to anti-inflammatory effects mediated via TNFα and COX2. These results provide directions for further study to 
develop novel therapeutic strategies to prevent pathophysiological alterations in pulmonary hypertension.
Materials and Methods
Experimental diets. The experimental diet was designed to test the effect of the combined nutritional inter-
vention consisting of extra protein, leucine, oligosaccharides and fish oil added to the background diet AIN-93M 
(Research Diet Services, Wijk bij Duurstede, the Netherlands). The control diet was isocaloric to the experimental 
diet, and contained per kg feed 110,3 g protein (casein), 53,6 g fat (corn oil), and 653,1 g carbohydrates. The isoca-
loric experimental diet (further referred to as Nutritional Intervention; NI) contained per kg feed: 210 g protein 
(189 g intact protein of which 68% casein and 32% whey and 21 g free leucine), 57 g fat (20.2 g corn oil, 10.2 g 
rapeseed oil, and 22.2 g fish oil (providing 6.9 g EPA and 3.1 g DHA)), 561 g carbohydrates, 18 g galacto-oligosac-
charides and 2 g fructo-oligosaccharides. Both diets were supplied as pellets.
Animals and study design. All experiments and procedures were approved by the local Animal Research 
Council, University of Leipzig and the Landesbehörde Sachsen (TVV 39/17). All experiments were performed in 
accordance with relevant guidelines and regulations.
This study included three groups of female C57BL/6 mice (aged 8 weeks) mice: 1) saline-treated (sham; 
n = 9); 2) monocrotaline (MCT)-treated fed standard semi-synthetic diet AIN-93M (MCT; 600 mg/kg; n = 9); 
and 3) MCT-treated fed an isocaloric semi-synthetic diet with high protein, leucine, oligosaccharides and fish 
oil (MCT + NI; n = 10). MCT was given weekly by subcutaneous injection and sham mice received a matched 
volume of saline during 8 weeks. During that time period, MCT is known to induce pulmonary hypertension 
and RV dysfunction15,16. Mice were exposed to identical conditions under a 12:12 h light/dark cycle with food 
and water provided ad libitum. All groups received their treatment diet one week prior to the MCT injections. 
Body weight and food intake were recorded every week. Mice were sacrificed following deep anesthetization 
with i.p. administration of fentanyl (0.05 mg/kg), medetomidine (0.5 mg/kg), midazolam (5 mg/kg) and ketamine 
(100 mg/kg). At sacrifice, the heart, lungs, tibialis anterior (TA), soleus and extensor digitorum longus (EDL) were 
dissected, cleaned, blotted dry and weighed and tibia length was measured. A medial section of the heart was 
fixed in 4% PBS-buffered formalin. The RV was dissected from the left ventricle and immediately frozen in liquid 
N2 for RNA and protein analysis. The lungs were dried at 37 °C to measure wet/dry lung weight.
Tissue analyses. RNA isolation and quantification of mRNA expression. Total RNA was isolated from RV 
tissue and reverse transcribed into cDNA using random hexamers and Sensiscript Reverse Transcriptase (Qiagen, 
Hilden, Germany). An aliquot of the cDNA was used for quantitative RT-PCR. The expression of specific genes 
was normalized to the expression of hypoxanthin phosphoribosyltransferase (HPRT) mRNA. For quantification 
of expression of specific genes, primers listed in Table 1 were used. For tumor necrosis factor alpha (TNFα) com-
mercial primers for SYBR Green assay were used (PrimePCR, Biorad laboratories).
Western blot analysis. Frozen TA muscle samples were homogenized in relax buffer (90 mmol/L HEPES, 
126 mmol/L KCl, 36 mmol/L NaCl, 1 mmol/L MgCl, 50 mmol/L EGTA, 8 mmol/L ATP,10 mmol/L creatine 
phosphate; pH 7.4) containing a protease inhibitor mix (inhibitor mix M, Serva, Heidelberg,Germany) and 
sonicated. Protein concentration was determined (bicinchoninic acid assay, Pierce, Bonn,Germany), and ali-
quots (5 μg) were separated by SDS-polyacrylamide gel electrophoresis (10% gels). Proteins were transferred 
to a polyvinylidene fluoride membrane and incubated overnight at 4 °C with the following primary antibodies: 
MuRF1 (1/1000, Myomedix Ltd., Neckargemünd, Germany) or MuRF2 (1/1600, Myomedix Ltd., Neckargemünd, 
Germany). Membranes were subsequently incubated with a horseradish peroxidase-conjugated secondary anti-
body and specific bands visualized by enzymatic chemiluminescence (Super Signal West Pico, Thermo Fisher 
Scientific Inc.,Bonn, Germany) and densitometry quantified using a 1D scan software package (Vision-Capt, 
Vilber Lourmat, Eberhardzell, Germany). Blots were then normalized to the loading control GAPDH (1/30 000; 
HyTest Ltd., Turku, Finland).
Histology. Paraffin-embedded medial cross sections (3 μm) of the heart, TA, soleus and EDL were mounted 
on glass slides. Subsequently, slides of the heart were stained with H&E and Picrosirius red to assess right ventricle 







Tabel 1. Sequences of quantitative RT-PCR primers.
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wall thickness and fibrosis by imaging software (ImageJ, 1.51d, NIH and Sigma Scan Pro 5.0, Systat Software 
Inc). Slides of the TA and EDL were stained with H&E to assess muscle fiber cross-sectional area by imaging 
software (ImageJ, 1.51d, NIH). Fiber type and cross-sectional area (CSA) of the soleus were analyzed by immu-
nohistochemistry; after target retrieval with Signal Stain Citrate solution (Cell Signaling), the slides were covered 
with proteinase K solution (Sigma, P2308), peroxidase and protein block (Dako), then incubated with anti-slow 
skeletal myosin heavy chain (Abcam, ab11083) in antibody dilution with background reducing factor (Dako) 
and anti-mouse HRP (Sigma 9044) in antibody dilution with background reducing factor (Dako). Development 
was performed with DAB+ coloring agent (Dako) and nuclei were colored with Mayer’s Hematoxylin Solution.
Microarray analysis. Total RNA from the right ventricle was isolated using trizol. RNA concentrations were 
measured by absorbance at 260 nm (nanodrop). RNA quality was checked using the RNA 6000 nano kit assay on 
the Agilent 2100 bioanalyser (Agilent Technologies, Amsterdam, The Netherlands) according to the manufac-
turer’s protocol. For each mouse, total RNA (100 ng) was labelled using the Affymetrix WT plus reagent kit (Life 
Technologies, Bleiswijk, The Netherlands).
Microarray experiments were performed using Affymetrix mouse gene 1.1 ST arrays. From the experiment, 3 
control samples, 3 MCT samples and 3 MCT + NI samples that were matched for disease severity were included 
in this experiment. Array data were analyzed using an in-house, online system44. Arrays passed quality control, 
so no samples had to be excluded from analysis. Briefly, probe sets were redefined according to Dai et al.45, using 
remapped computable document format version 19 based on the Entrez gene database. In total these arrays 
target 21.114 unique genes. Normalized expression estimates were obtained from the raw intensity values using 
the robust multi-array analysis (RMA) preprocessing algorithm available in the library ‘affyPLM’ using default 
settings46. Differentially expressed probe sets were identified using linear models, applying moderated t-statistics 
that implemented intensity-based empirical Bayes regularization of standard errors (library ‘limma’). The moder-
ated t-test statistic has the same interpretation as an ordinary t-test statistic, except that the standard errors have 
been moderated across genes, i.e. shrunk to a common value, using a Bayesian model47,48. Probe sets that satisfied 
the criterion of P < 0.01 or P < 0.05 (depending on the research question) were considered to be significantly 
regulated.
Changes in gene expression were related to biologically meaningful changes using gene set enrichment analy-
sis (GSEA) of broadinstitute.org49. Gene sets were retrieved from the expert-curated Kyoto Encyclopedia of Genes 
and Genomes (KEGG), Biocarta, Reactome and WikiPathways pathway databases. Only gene sets consisting of 
more than 15 and fewer than 500 genes were taken into account, which resulted in the inclusion of 1,382 gene 
sets. For each comparison, genes were ranked on their t-value that was calculated by the empirical Bayes method. 
Statistical significance of GSEA results was determined using 1,000 permutations.
The array data has been submitted to the Gene Expression Omnibus (GEO)50, under accession number 
GSE125537.
Statistical analyses. Data are presented as mean ± SD. One-way analysis of variance (ANOVA) followed by 
Tukey post hoc was used to compare groups (GraphPad Prism). Significance was accepted as P < 0.05.
Data Availability
The array data generated and analysed during the current study has been submitted to the Gene Expression Om-
nibus (GEO)50, under accession number GSE125537. The GSEA datasets are available from the Supplementary 
Information files. Other analysed datasets are available from the corresponding author on reasonable request.
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